Showing 4931-4940 of 20470 results for "".
- Markers Correlated with Severe Pediatric Adenovirus Pneumoniahttps://reachmd.com/news/markers-severe-pediatric-adenovirus-pneumonia/2486093/In a pediatric adenovirus pneumonia cohort, investigators in China examined whether routine laboratory indices and a serum cytokine panel differed betwee
- NOA Longitudinal Validation On Home OCT for AMDhttps://reachmd.com/news/noa-longitudinal-validation-on-home-oct-for-amd/2486082/Longitudinal home OCT data were used to evaluate whether an artificial intelligence system can distinguish meaningful disease-activity change from stability when patients self-image frequently outside the clinic.
- FINERENONE (KERENDIA) Meets Primary Endpoint in FIND‑CKDhttps://reachmd.com/news/finerenone-kerendia-meets-primary-endpoint-in-findckd/2486094/Bayer reported that the Phase III FIND‑CKD study met its predefined primary endpoint, describing a statistically signif
- Racial and Biological Diversity in Early Alzheimer Brain Markershttps://reachmd.com/news/racial-and-biological-diversity-in-early-alzheimer-brain-markers/2486071/Investigators working within the Health and Aging Brain Study–Health Disparities (HABS-HD) imaging effort reported that early Alzheimer disease–related biomarker patterns differed across ethnoracial groups
- ADorable-1 Trial Meets Endpoints for EBGLYSS in Children With Atopic Dermatitishttps://reachmd.com/news/adorable-1-trial-meets-endpoints-for-ebglyss-in-children-with-atopic-dermatitis/2486087/Eli Lilly and Company announced positive topline results from the phase 3 ADorable-1 trial of lebrikizumab-lbkz (Ebglyss) in pediatric patients aged 6 months to 18 years with moderate-to-severe atopic dermatitis (AD), showing the therapy meeting its primary and sec
- OFDI Shows Acute Thrombus and Healed Plaque in Symptomatic Femoropopliteal Lesionshttps://reachmd.com/news/ofdi-shows-acute-thrombus-and-healed-plaque-in-symptomatic-femoropopliteal-lesions/2486074/A recent American Journal of Cardiology abstract describes the use of optical frequency domain imaging (OFDI) in symptomatic femoropoplit
- Conversational AI (AMIE) in Urgent Care: Feasibility and Early Findingshttps://reachmd.com/news/conversational-ai-amie-in-urgent-care-feasibility-and-early-findings/2486067/A recent report describes a prospective, single-arm feasibility study that placed Google’s conversational diagnostic AI, the Articulate Medical Intelligence E
- Treatment Gaps and Outcomes for Adolescents with ADHD and SUDhttps://reachmd.com/news/news-summary-treatment-gaps-and-outcomes-for-adolescents-with-adhd-and-sud/2486070/A retrospective analysis of de-identified health records in people ages 15–25 with ADHD and substance use disorder (SUD) is describ
- FDA Expands Secukinumab to Adolescents With Moderate to Severe HShttps://reachmd.com/news/fda-expands-secukinumab-to-adolescents-with-moderate-to-severe-hs/2486084/The US Food and Drug Administrationv (FDA) has approved secukinumab (Cosentyx, Novartis) for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa (HS), becoming the only IL-17A inhibitor approved for this group, according to a
- Research Describes Peptide-Guided Oral Tolerance and Translational Prospectshttps://reachmd.com/news/research-describes-peptide-guided-oral-tolerance-and-translational-prospects/2486053/Investigators in a recent study describe oral food tolerance as an active, peptide-guided immune process in which intestinal regulatory T cells (Tregs) preferentially recognize cer